Patricia T Illing Selected Research

HLA-B57 antigen

1/2021	Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire.
1/2020	Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA-B*57:01 binding and T-cell activation.
11/2018	HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome.
1/2017	The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.
10/2016	Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions.
2/2013	Human leukocyte antigen-associated drug hypersensitivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patricia T Illing Research Topics

Disease

8	Hypersensitivity (Allergy) 01/2021 - 06/2012
6	Infections 01/2022 - 01/2018
5	Drug Hypersensitivity (Drug Allergy) 01/2021 - 02/2013
5	Drug-Related Side Effects and Adverse Reactions 01/2019 - 02/2013
4	Human Influenza (Influenza) 01/2022 - 01/2019
3	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2021 - 06/2012
2	Neoplasms (Cancer) 01/2021 - 12/2020
2	Virus Diseases (Viral Diseases) 01/2018 - 10/2014
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 01/2019
1	Exanthema (Rash) 01/2019
1	Neuralgia (Stump Neuralgia) 01/2019
1	Epilepsy (Aura) 01/2019
1	Drug Hypersensitivity Syndrome 01/2019
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2019
1	Inflammation (Inflammations) 01/2018
1	Skin Diseases (Skin Disease) 10/2017
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2017
1	Vesiculobullous Skin Diseases (Subcorneal Pustular Dermatosis) 02/2013

Drug/Important Bio-Agent (IBA)

10	Peptides (Polypeptides)IBA 01/2022 - 06/2012
6	abacavir (Ziagen)FDA Link 01/2021 - 06/2012
6	HLA-B57 antigenIBA 01/2021 - 02/2013
4	Pharmaceutical PreparationsIBA 01/2021 - 06/2012
4	HLA Antigens (Human Leukocyte Antigens)IBA 11/2018 - 02/2013
3	VaccinesIBA 01/2022 - 01/2019
3	Carbamazepine (Tegretol)FDA LinkGeneric 01/2021 - 06/2012
3	HLA-B Antigens (HLA-B)IBA 11/2018 - 06/2012
2	HLA-A*24:02 antigenIBA 01/2022 - 01/2021
2	HLA-A Antigens (HLA-A)IBA 01/2022 - 01/2022
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2022
1	Antiviral Agents (Antivirals)IBA 12/2021
1	oridoninIBA 12/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Penicillins (Penicillin)FDA Link 01/2021
1	AntigensIBA 01/2021
1	beta Lactam AntibioticsIBA 01/2021
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2019
1	Histocompatibility Antigens Class IIBA 01/2019
1	Tryptophan (L-Tryptophan)FDA Link 01/2018
1	KynurenineIBA 01/2018
1	HLA-C Antigens (HLA-C)IBA 10/2017
1	AutoantigensIBA 10/2017

Therapy/Procedure

1	Immunotherapy 01/2021
1	Transplantation 11/2018